Outcome measures of instrumented gait analysis in hereditary spastic paraplegia: a systematic review.

BACKGROUND

Hereditary spastic paraplegias (HSPs) comprise a group of genetic movement disorders characterized by progressive spasticity and weakness of the lower limbs leading to gait deficits. Instrumented gait measures are applied to quantify gait patterns in HSP objectively. However, there is no consensus on the most relevant HSP-specific digital outcome measures for future clinical studies.

AIM

This systematic review aims to summarize outcome measures of instrumented gait analysis in HSP patients, focusing on both traditional motion capture (MOCAP) and inertial sensor systems.

METHODS

Following PRISMA-2020 guidelines, a comprehensive literature search was conducted in PubMed, Scopus, and Web of Science to identify studies using instrumented gait analysis in HSP. Data on participant characteristics, measurement systems, outcome measures, results, and risk of bias were systematically extracted.

RESULTS

In total, 38 studies published between 2004 and 2024, including 29 observational studies and 9 interventional studies, met the inclusion criteria. Various gait parameters were used, including spatio-temporal, kinematic, kinetic, and electromyography (EMG) parameters. Walking speed and range-of-motion (ROM) knee were identified as important parameters for differentiating HSP patients from healthy controls, but these parameters are more general rather than disease-specific. Foot lift, ROM foot, and gait variability are promising, more disease-specific parameters, as they reflect disease severity and increased balance deficits. However, a deeper understanding of all gait parameter categories is necessary, particularly for the upper body. Few studies explored sub-cohorts that exhibit different HSP gait characteristics.

CONCLUSION

While MOCAP provides valuable data in controlled hospital environments, there is a need for validated mobile sensor systems capturing the gait patterns of HSP patients in real-life without supervision. Future research must focus on better longitudinal multicenter studies with larger sample sizes to establish robust digital outcomes and monitor disease progression and therapeutic response in HSP.